These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 35236838)

  • 21. Emerging Technologies for Low-Cost, Rapid Vaccine Manufacture.
    Kis Z; Shattock R; Shah N; Kontoravdi C
    Biotechnol J; 2019 Jan; 14(1):e1800376. PubMed ID: 30537361
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Vaccines' New Era-RNA Vaccine.
    Zhou W; Jiang L; Liao S; Wu F; Yang G; Hou L; Liu L; Pan X; Jia W; Zhang Y
    Viruses; 2023 Aug; 15(8):. PubMed ID: 37632102
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Adenoviral vector vaccine platforms in the SARS-CoV-2 pandemic.
    Mendonça SA; Lorincz R; Boucher P; Curiel DT
    NPJ Vaccines; 2021 Aug; 6(1):97. PubMed ID: 34354082
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The baculovirus expression vector system: a modern technology for the future of influenza vaccine manufacturing.
    Trombetta CM; Marchi S; Montomoli E
    Expert Rev Vaccines; 2022 Sep; 21(9):1233-1242. PubMed ID: 35678205
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Current Status and Future Perspectives on MRNA Drug Manufacturing.
    Webb C; Ip S; Bathula NV; Popova P; Soriano SKV; Ly HH; Eryilmaz B; Nguyen Huu VA; Broadhead R; Rabel M; Villamagna I; Abraham S; Raeesi V; Thomas A; Clarke S; Ramsay EC; Perrie Y; Blakney AK
    Mol Pharm; 2022 Apr; 19(4):1047-1058. PubMed ID: 35238565
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Sustainable vaccine manufacturing in low- and middle-Income countries.
    Hayman B; Kumar Suri R; Downham M
    Vaccine; 2022 Nov; 40(50):7288-7304. PubMed ID: 36334966
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Real-world effectiveness of the inactivated COVID-19 vaccines against variant of concerns: meta-analysis.
    Sarwar MU; Waasia FZ; Aloqbi AA; Alandiyjany M; Alqahtani RM; Hafiz LA; Shamlan G; Albreiki M
    J Infect Public Health; 2024 Feb; 17(2):245-253. PubMed ID: 38141544
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A systems immunology study comparing innate and adaptive immune responses in adults to COVID-19 mRNA and adenovirus vectored vaccines.
    Ryan FJ; Norton TS; McCafferty C; Blake SJ; Stevens NE; James J; Eden GL; Tee YC; Benson SC; Masavuli MG; Yeow AEL; Abayasingam A; Agapiou D; Stevens H; Zecha J; Messina NL; Curtis N; Ignjatovic V; Monagle P; Tran H; McFadyen JD; Bull RA; Grubor-Bauk B; Lynn MA; Botten R; Barry SE; Lynn DJ
    Cell Rep Med; 2023 Mar; 4(3):100971. PubMed ID: 36871558
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Vaccine complacency and dose distribution inequities limit the benefits of seasonal influenza vaccination, despite a positive trend in use.
    Palache A; Rockman S; Taylor B; Akcay M; Billington JK; Barbosa P;
    Vaccine; 2021 Oct; 39(41):6081-6087. PubMed ID: 34521551
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The Importance of RNA-Based Vaccines in the Fight against COVID-19: An Overview.
    Machado BAS; Hodel KVS; Fonseca LMDS; Mascarenhas LAB; Andrade LPCDS; Rocha VPC; Soares MBP; Berglund P; Duthie MS; Reed SG; Badaró R
    Vaccines (Basel); 2021 Nov; 9(11):. PubMed ID: 34835276
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A Cross-sectional Survey of Public Knowledge and Perspective on Coronavirus Disease, Vaccination, and Related Research in India during the COVID-19 Pandemic.
    Munshi R; Maurya M
    J Assoc Physicians India; 2023 Sep; 71(9):19-27. PubMed ID: 38700297
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pivoting to protein: the immunogenicity and safety of protein-based NVX-CoV2373 as a heterologous booster for inactivated and viral vector COVID-19 vaccines.
    Marchese AM; Kalkeri R; Vadivale M; Suntronwong N; Toback S; Poovorawan Y
    Expert Rev Vaccines; 2023; 22(1):620-628. PubMed ID: 37386785
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Interchangeability of different COVID-19 vaccine platforms as booster doses: A phase 3 study mimicking real-world practice.
    Ann Costa Clemens S; Weckx L; Milan EP; Smolenov I; Clemens R
    Vaccine; 2024 Jul; 42(19):3989-3998. PubMed ID: 38762360
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Global pandemic preparedness: learning from the COVID-19 vaccine development and distribution.
    Agampodi S; Mogeni OD; Chandler R; Pansuriya M; Kim JH; Excler JL
    Expert Rev Vaccines; 2024; 23(1):761-772. PubMed ID: 39167221
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Adenoviral Vector-Based Vaccine Platform for COVID-19: Current Status.
    Chavda VP; Bezbaruah R; Valu D; Patel B; Kumar A; Prasad S; Kakoti BB; Kaushik A; Jesawadawala M
    Vaccines (Basel); 2023 Feb; 11(2):. PubMed ID: 36851309
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immunogenicity and clinical features relating to BNT162b2 messenger RNA COVID-19 vaccine, Ad26.COV2.S and ChAdOx1 adenoviral vector COVID-19 vaccines: a systematic review of non-interventional studies.
    Iheanacho CO; Eze UIH
    Futur J Pharm Sci; 2022; 8(1):20. PubMed ID: 35368622
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Global Pandemic Preparedness: Optimizing Our Capabilities and the Influenza Experience.
    Rockman S; Taylor B; McCauley JW; Barr IG; Longstaff R; Bahra R
    Vaccines (Basel); 2022 Apr; 10(4):. PubMed ID: 35455338
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Global diversity of policy, coverage, and demand of COVID-19 vaccines: a descriptive study.
    Chen Z; Zheng W; Wu Q; Chen X; Peng C; Tian Y; Sun R; Dong J; Wang M; Zhou X; Zhao Z; Zhong G; Yan X; Liu N; Hao F; Zhao S; Zhuang T; Yang J; Azman AS; Yu H
    BMC Med; 2022 Apr; 20(1):130. PubMed ID: 35369871
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Viral vector and nucleic acid vaccines against COVID-19: A narrative review.
    Khoshnood S; Ghanavati R; Shirani M; Ghahramanpour H; Sholeh M; Shariati A; Sadeghifard N; Heidary M
    Front Microbiol; 2022; 13():984536. PubMed ID: 36118203
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Persistence of immune response in heterologous COVID vaccination schedules in the Com-COV2 study - A single-blind, randomised trial incorporating mRNA, viral-vector and protein-adjuvant vaccines.
    Shaw RH; Greenland M; Stuart ASV; Aley PK; Andrews NJ; Cameron JC; Charlton S; Clutterbuck EA; Collins AM; Darton T; Dinesh T; Duncan CJA; Faust SN; Ferreira DM; Finn A; Goodman AL; Green CA; Hallis B; Heath PT; Hill H; Lambe T; Libri V; Lillie PJ; Morey E; Mujadidi YF; Payne R; Plested EL; Provstgaard-Morys S; Ramasamy MN; Ramsay M; Read RC; Robinson H; Screaton GR; Singh N; Turner DPJ; Turner PJ; White R; Nguyen-Van-Tam JS; Liu X; Snape MD;
    J Infect; 2023 Jun; 86(6):574-583. PubMed ID: 37028454
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.